amifostine anhydrous has been researched along with Hyperparathyroidism in 6 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lefebvre, J | 1 |
| Hirschel-Scholz, S | 3 |
| Caverzasio, J | 3 |
| Bonjour, JP | 3 |
| Morita, M | 1 |
| Higashi, K | 1 |
| Tajiri, J | 1 |
| Sato, T | 1 |
| Larsson, R | 1 |
| Nygren, P | 1 |
| Wallfelt, C | 1 |
| Akerström, G | 1 |
| Rastad, J | 1 |
| Ljunghall, S | 1 |
| Gylfe, E | 1 |
2 reviews available for amifostine anhydrous and Hyperparathyroidism
| Article | Year |
|---|---|
Possibilities and limits of the medical treatment for primary hyperparathyroidism.
Topics: Amifostine; Humans; Hypercalcemia; Hyperparathyroidism; Parathyroid Hormone | 1989 |
Mechanism of the hypocalcemic agent WR-2721 and its acute and chronic application in eu- and hyperparathyroidism.
Topics: Amifostine; Animals; Bone Resorption; Humans; Hypercalcemia; Hyperparathyroidism; Magnesium; Organot | 1986 |
4 other studies available for amifostine anhydrous and Hyperparathyroidism
| Article | Year |
|---|---|
Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent.
Topics: Amifostine; Animals; Calcium; Cyclic AMP; Hyperparathyroidism; Kidney Tubules; Magnesium; Male; Orga | 1985 |
S-2-(3-Aminopropylamino)ethyl phosphorothioic acid (WR-2721) in primary hyperparathyroidism.
Topics: Amifostine; Calcium; Humans; Hyperparathyroidism; Organothiophosphorus Compounds; Parathyroid Hormon | 1985 |
Dual effects of a new hypocalcemic agent, WR-2721, on cytoplasmic Ca2+ and parathyroid hormone release of dispersed parathyroid cells from patients with hyperparathyroidism.
Topics: Amifostine; Calcium; Cytoplasm; Humans; Hyperparathyroidism; In Vitro Techniques; Membrane Potential | 1986 |
Prevention of parathyroid hormone-dependent nephrocalcinosis by chronic administration of the organic phosphorothioate WR-2721.
Topics: Amifostine; Animals; Calcinosis; Calcitriol; Calcium; Cyclic AMP; Glomerular Filtration Rate; Hyperp | 1987 |